SOT Medical Systems announces a change in its management structure effective April 8, 2026.
Karl Glantschnig, founder and long-standing Managing Director, stepped down from his leadership role within the company.
Over the years, Karl has played a central role in establishing Austrian family business SOT Medical Systems as an innovative provider in the field of vascular diagnostics. His contributions have significantly shaped the company’s strategic direction, product development, and international growth. Following his transition, he will remain closely involved with the company as Founder and Scientific Advisor, continuing to contribute his expertise to ongoing scientific and clinical developments.
As part of this transition, Marc Glantschnig and Miguel Marhl will assume joint leadership of SOT Medical Systems as equal Managing Directors. The new management structure reflects a commitment to continuity while supporting the further development of the company’s portfolio and international activities.
The leadership change marks the beginning of the next phase in the company’s development. SOT Medical Systems will continue to focus on advancing modern, efficient, and clinically relevant solutions in vascular diagnostics, with a strong emphasis on early detection, standardisation, and integration into routine clinical workflows.
As the founder of the company, I am delighted to be able to hand over the reins to a dynamic, long-standing duo. I am confident that the high level of customer satisfaction we have achieved so far will not only be maintained but further enhanced, and that SOT Medical Systems will gain even greater recognition in the field of vascular diagnostics.
By strategically combining our strengths in product development and international expansion, we are consistently driving the company’s growth. We are grateful to be able to build upon a solid foundation of 38 years of company history.
I look forward to working with Marc Glantschnig to guide the family business into a new phase of growth. Our goal remains to develop the best vascular diagnostic systems and make them available to as many people as possible.
The transition ensures stability in strategic direction while enabling continued growth and innovation in the global MedTech landscape.
